Tuesday October 23, 2018 21:32

Heathcare Press Release : 05 Jun 2018

Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with Heathcare—05 Jun 18

- Two-year follow-up data on meaningful durable response, overall survival (OS) and progression-free survival (PFS) to be presented in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin cancer Merck and Pfizer

Merck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO Heathcare—05 Jun 18

M7824 (TGF-ss trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt inhibitor): 2584; M6620 (ATR inhibitor): 2549; M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - M7824 is an